Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:THRX

Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis

Theseus Pharmaceuticals logo

About Theseus Pharmaceuticals Stock (NASDAQ:THRX)

Key Stats

Today's Range
$4.06
$4.06
50-Day Range
$4.06
$4.07
52-Week Range
$2.05
$12.37
Volume
N/A
Average Volume
592,167 shs
Market Capitalization
$179.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Receive THRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

THRX Stock News Headlines

The True Cost of Layoffs
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Theseus Pharmaceuticals Announces Closing of Tender Offer
See More Headlines

THRX Stock Analysis - Frequently Asked Questions

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($5.16) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $4.93.

Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theseus Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD).

Company Calendar

Last Earnings
11/15/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:THRX
Fax
N/A
Employees
38
Year Founded
N/A

Profitability

Net Income
$-50,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.36 per share

Miscellaneous

Free Float
23,575,000
Market Cap
$179.57 million
Optionable
Optionable
Beta
3.98
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:THRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners